An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia
What is the purpose of this trial?
CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).
- Trial withCelgene Corporation
- Start Date09/22/2022
- End Date04/28/2023
- Last Updated11/15/2022
- Study HIC#2000027204